C3-convertase inhibitors for the prevention and treatment of...

C - Chemistry – Metallurgy – 12 – Q

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12Q 1/68 (2006.01)

Patent

CA 2631958

The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.

La présente invention concerne des procédés pour l'identification de patients susceptibles de développer la dégénérescence maculaire liée à l'âge par l'identification de la présence du polymorphisme Y402H ou d'autres variants à risque dans le gène de facteur H du complément. La présente invention concerne également des procédés pour le traitement de personnes atteintes de la dégénérescence maculaire liée à l'âge ou susceptibles de développer la dégénérescence maculaire liée à l'âge conséquente à la présence du polymorphisme Y402H ou d'autres variants à risque dans le gène de facteur H du complément.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

C3-convertase inhibitors for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C3-convertase inhibitors for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C3-convertase inhibitors for the prevention and treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1792221

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.